Remdesivir influence on course of new coronaviral infection in pregnant

Q4 Medicine Infektsionnye Bolezni Pub Date : 2022-01-01 DOI:10.20953/1729-9225-2022-1-16-22

O. Tumash, A. M. Karamyshau, I. Stoma, M. N. Menshakova, I. O. Vakulchik

{"title":"Remdesivir influence on course of new coronaviral infection in pregnant","authors":"O. Tumash, A. M. Karamyshau, I. Stoma, M. N. Menshakova, I. O. Vakulchik","doi":"10.20953/1729-9225-2022-1-16-22","DOIUrl":null,"url":null,"abstract":"Objective. To estimate efficiency and safety of remdesivir in treating new coronavirus infection in pregnant. Materials and methods. A retrospective cohort study including 61 medical patient’s records who underwent COVID-19 and being pregnant more than 20 weeks was conducted. Medical case histories were divided into 2 groups: the main one with the use of remdesivir treatment (n = 35) and control one (n = 26) without it. The groups were representative by age, anthropometric data and comorbidity (p > 0.05). Results. The use of remdesivir in pregnant patients with COVID-19 causes a reduction in fever by 15% and achievement of target saturation values in 94.3% of cases, reduces С-reaction protein (CRP) levels by 3.5 times, D-dimer by 2.6, Lactat Dehydrogenase (LDG) by 1.4 times on 5th day from the moment of hospitalization, reduces its duration by 30.8%, does not affect the course of pregnancy and the frequency of Cesarean section. Conclusion. The use of remdesivir in the treatment of COVID-19 in pregnant patients with a gestation period of more than 20 weeks is effective, as evidenced by the shortening of the fever period, the duration of hospitalization, improving oxygenation, reduction of laboratory markers \"cytokine storm\" in blood levels and safe due to the lack of impact on pregnancy and delivery strategy. Key words: СOVID-19, cytokine storm, laboratory criteria, pregnancy, remdesivir","PeriodicalId":37794,"journal":{"name":"Infektsionnye Bolezni","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infektsionnye Bolezni","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/1729-9225-2022-1-16-22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Objective. To estimate efficiency and safety of remdesivir in treating new coronavirus infection in pregnant. Materials and methods. A retrospective cohort study including 61 medical patient’s records who underwent COVID-19 and being pregnant more than 20 weeks was conducted. Medical case histories were divided into 2 groups: the main one with the use of remdesivir treatment (n = 35) and control one (n = 26) without it. The groups were representative by age, anthropometric data and comorbidity (p > 0.05). Results. The use of remdesivir in pregnant patients with COVID-19 causes a reduction in fever by 15% and achievement of target saturation values in 94.3% of cases, reduces С-reaction protein (CRP) levels by 3.5 times, D-dimer by 2.6, Lactat Dehydrogenase (LDG) by 1.4 times on 5th day from the moment of hospitalization, reduces its duration by 30.8%, does not affect the course of pregnancy and the frequency of Cesarean section. Conclusion. The use of remdesivir in the treatment of COVID-19 in pregnant patients with a gestation period of more than 20 weeks is effective, as evidenced by the shortening of the fever period, the duration of hospitalization, improving oxygenation, reduction of laboratory markers "cytokine storm" in blood levels and safe due to the lack of impact on pregnancy and delivery strategy. Key words: СOVID-19, cytokine storm, laboratory criteria, pregnancy, remdesivir

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

瑞德西韦对孕妇新型冠状病毒感染过程的影响

目标。评价瑞德西韦治疗妊娠期新型冠状病毒感染的有效性和安全性。材料和方法。对61例怀孕20周以上的新冠肺炎患者进行回顾性队列研究。病历分为两组:使用瑞德西韦治疗的主要组(35例)和未使用瑞德西韦治疗的对照组(26例)。各组在年龄、人体测量数据和合并症方面具有代表性(p < 0.05)。结果。使用瑞德西韦治疗妊娠COVID-19患者，94.3%患者发热降低15%，达到目标饱和度，住院第5天С-reaction蛋白(CRP)水平降低3.5倍，d -二聚体降低2.6倍，乳酸脱氢酶(LDG)水平降低1.4倍，持续时间减少30.8%，不影响妊娠过程和剖宫产次数。结论。瑞德西韦治疗妊娠期超过20周的COVID-19妊娠患者是有效的，表现为发热期缩短，住院时间缩短，氧合改善，血液中实验室标志物“细胞因子风暴”水平降低，对妊娠和分娩策略没有影响，安全。关键词:СOVID-19，细胞因子风暴，实验室标准，妊娠，瑞德西韦

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Infektsionnye Bolezni Medicine-Infectious Diseases

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： The journal publishes original research works, reviews of literature, lectures, methodological recommendations, clinical observations. Main topics: problems of etiology, pathogenesis, clinical manifestations of infectious diseases, new techniques and methods of their diagnosis, prevention and treatment; special attention is paid to the problems of antibacterial and antiviral therapy, the use of immunoglobulins and interferons, and also to intensive therapy of critical states. The journal is in the List of leading scientific journals and periodicals of the Supreme Attestation Committee, where the principal results of doctoral dissertations should be published.